B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma

Abstract

Aim: Neuroblastoma is the most common extracranial solid tumor in children. Recent advances in immunotherapy Approaches, including in neuroblastoma, have shown the important role of the immune system in mounting an effective anti-tumor response. In this study, we aimed to provide a comprehensive investigation of immune cell infiltration in neuroblastoma utilizing a large number of gene expression datasets.

Methods: We inferred immune cell infiltration using an established immune inference method and evaluated the association between immune cell abundance and patient prognosis as well as common chromosomal abnormalities found in neuroblastoma. In addition, we evaluated co-infiltration patterns among distinct immune cell types.

Results: The infiltration of naïve B cells, NK cells, and CD8+ T cells was associated with improved patient prognosis. Naïve B cells were the most consistent indicator of prognosis and associated with an active immune tumor microenvironment. Patients with high B cell infiltration showed high co-infiltration of other immune cell types and the enrichment of immune-related pathways. The presence of high B cell infiltration was associated with both recurrence-free and overall survival, even after adjusting for clinical variables.

Conclusion: In this study, we have provided a comprehensive evaluation of immune cell infiltration in neuroblastoma using gene expression data. We propose an important role for B cells in the neuroblastoma tumor microenvironment and suggest that B cells can be used as a prognostic biomarker to predict recurrence-free and overall survival independently of currently utilized prognostic variables.

Keywords

Neuroblastoma / immune cell infiltration / prognosis / MYCN amplification / B cells

References

[1] Smith MA,Altekruse SF.Outcomes for children and adolescents with cancer: challenges for the twenty-first century.J Clin Oncol2010;28:2625-34 PMCID:PMC2881732

[2] Matthay KK,Schleiermacher G.Neuroblastoma.Nat Rev Dis Primers2016;2:16078

[3] Maris JM.Recent advances in neuroblastoma.N Engl J Med2010;362:2202-11 PMCID:PMC3306838

[4] Mossé YP,Longo L.Identification of ALK as a major familial neuroblastoma predisposition gene.Nature2008;455:930-5 PMCID:PMC2672043

[5] Mosse YP,Khazi D.Germline PHOX2B mutation in hereditary neuroblastoma.Am J Hum Genet2004;75:727-30 PMCID:PMC1182065

[6] Yan P,Bian L.Comparison of incidence and outcomes of neuroblastoma in children, adolescents, and adults in the United States: a Surveillance, Epidemiology, and End Results (SEER) program population study.Med Sci Monit2020;26:e927218 PMCID:PMC7711874

[7] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer2012;12:252-64 PMCID:PMC4856023

[8] Yu AL,Ozkaynak MF.Children's Oncology GroupAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.N Engl J Med2010;363:1324-34 PMCID:PMC3086629

[9] Zhang P,Basu M.MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico immunological analysis of TARGET database.Front Immunol2017;8:1473 PMCID:PMC5675839

[10] Wei JS,Zhang S.Clinically relevant cytotoxic immune cell signatures and clonal expansion of T-Cell receptors in high-risk MYCN-not-amplified human neuroblastoma.Clin Cancer Res2018;24:5673-84 PMCID:PMC6504934

[11] Layer JP,Quast T.Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.Oncoimmunology2017;6:e1320626 PMCID:PMC5486176

[12] Zhong X,Wang L,Liu H.Cellular components in tumor microenvironment of neuroblastoma and the prognostic value.PeerJ2019;7:e8017 PMCID:PMC6910112

[13] Westermann F,Benner A.Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.Genome Biol2008;9:R150 PMCID:PMC2760877

[14] Oberthuer A,Li L.Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients.Pharmacogenomics J2010;10:258-66 PMCID:PMC2920066

[15] Henrich KO,Saadati M.Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas.Cancer Res2016;76:5523-37

[16] Munro SA,Pine PS.Assessing technical performance in differential gene expression experiments with external spike-in RNA control ratio mixtures.Nat Commun2014;5:5125

[17] Kocak H,Hero B.Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma.Cell Death Dis2013;4:e586 PMCID:PMC3668636

[18] Wang Q,Rappaport E.Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.Cancer Res2006;66:6050-62

[19] Rajbhandari P,Capdevila C.Cross-cohort analysis identifies a TEAD4-MYCN positive feedback loop as the core regulatory element of high-risk neuroblastoma.Cancer Discov2018;8:582-99 PMCID:PMC5967627

[20] Łastowska M,Santibanez-Koref M.Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.Oncogene2007;26:7432-44

[21] Ackermann S,Hero B.A mechanistic classification of clinical phenotypes in neuroblastoma.Science2018;362:1165-70 PMCID:PMC7875194

[22] Berwanger B,Bergmann E.Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.Cancer Cell2002;2:377-86

[23] Pugh TJ,Attiyeh EF.The genetic landscape of high-risk neuroblastoma.Nat Genet2013;45:279-84 PMCID:PMC3682833

[24] Varn FS,Mullins DW.Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles.Nat Commun2016;7:10248 PMCID:PMC4725766

[25] Varn FS,Mullins DW,Cheng C.Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment.Cancer Res2017;77:1271-82 PMCID:PMC5798883

[26] Cheng C,Sun F.Inferring activity changes of transcription factors by binding association with sorted expression profiles.BMC Bioinformatics2007;8:452 PMCID:PMC2194743

[27] Coughlin CM,Carroll RG.Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma.J Clin Oncol2006;24:5725-34

[28] Slyper M,Ashenberg O.A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors.Nat Med2020;26:792-802 PMCID:PMC7220853

[29] Helmink BA,Gao J.B cells and tertiary lymphoid structures promote immunotherapy response.Nature2020;577:549-55

[30] Petitprez F,Keung EZ.B cells are associated with survival and immunotherapy response in sarcoma.Nature2020;577:556-60

[31] Cabrita R,Sanna A.Tertiary lymphoid structures improve immunotherapy and survival in melanoma.Nature2020;577:561-5

[32] Maris JM,Bagatell R.Neuroblastoma.Lancet2007;369:2106-20 PMCID:PMC7115982

[33] der Leun AM, Thommen DS, Schumacher TN. CD8⁺ T cell states in human cancer: insights from single-cell analysis.Nat Rev Cancer2020;20:218-32 PMCID:PMC7115982

[34] Charoentong P,Angelova M.Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.Cell Rep2017;18:248-62

[35] Asgharzadeh S,Ji L.Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.J Clin Oncol2012;30:3525-32 PMCID:PMC3675667

[36] Rubtsov AV,Kappler JW,Friedman RS.CD11c-expressing B cells are located at the T Cell/B cell border in spleen and are potent APCs.J Immunol2015;195:71-9 PMCID:PMC4475418

[37] Shi JY,Wang ZC.Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma.Clin Cancer Res2013;19:5994-6005

[38] Coronella JA,Welch M.Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.J Immunol2002;169:1829-36

[39] Sharonov GV,Yuzhakova DV,Chudakov DM.B cells, plasma cells and antibody repertoires in the tumour microenvironment.Nat Rev Immunol2020;20:294-307

[40] Cavalli E,Mammana S.Overexpression of macrophage migration inhibitory factor and its homologue D-dopachrome tautomerase as negative prognostic factor in neuroblastoma.Brain Sci2019;9:284 PMCID:PMC6826588